Aims Arrhythmogenic right ventricular cardiomyopathy (ARVC) causes ventricular arrhythmias (VAs) and sudden cardiac death (SCD). In 2019, a risk prediction model that estimates the 5-year risk of incident VAs in ARVC was developed (ARVCrisk.com). This study aimed to externally validate this prediction model in a large international multicentre cohort and to compare its performance with the risk factor approach recommended for implantable cardioverter-defibrillator (ICD) use by published guidelines and expert consensus.Methods and results In a retrospective cohort of 429 individuals from 29 centres in North America and Europe, 103 (24%) experienced sustained VA during a median follow-up of 5.02 (2.05-7.90) years following diagnosis of ARVC. External validation yielded good discrimination [C-index of 0.70 (95% confidence interval-CI 0.65-0.75)] and calibration slope of 1.01 (95% CI 0.99-1.03). Compared with the three published consensus-based decision algorithms for ICD use in ARVC (Heart Rhythm Society consensus on arrhythmogenic cardiomyopathy, International Task Force consensus statement on the treatment of ARVC, and American Heart Association guidelines for VA and SCD), the risk calculator performed better with a superior net clinical benefit below risk threshold of 35%.Conclusion Using a large independent cohort of patients, this study shows that the ARVC risk model provides good prognostic information and outperforms other published decision algorithms for ICD use. These findings support the use of the model to facilitate shared decision making regarding ICD implantation in the primary prevention of SCD in ARVC.

Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator / Jordà, Paloma; Bosman, Laurens P; Gasperetti, Alessio; Mazzanti, Andrea; Gourraud, Jean Baptiste; Davies, Brianna; Frederiksen, Tanja Charlotte; Weidmann, Zoraida Moreno; Di Marco, Andrea; Roberts, Jason D; MacIntyre, Ciorsti; Seifer, Colette; Delinière, Antoine; Alqarawi, Wael; Kukavica, Deni; Minois, Damien; Trancuccio, Alessandro; Arnaud, Marine; Targetti, Mattia; Martino, Annamaria; Oliviero, Giada; Pipilas, Daniel C; Carbucicchio, Corrado; Compagnucci, Paolo; Dello Russo, Antonio; Olivotto, Iacopo; Calò, Leonardo; Lubitz, Steven A; Cutler, Michael J; Chevalier, Philippe; Arbelo, Elena; Priori, Silvia Giuliana; Healey, Jeffrey S; Calkins, Hugh; Casella, Michela; Jensen, Henrik Kjærulf; Tondo, Claudio; Tadros, Rafik; James, Cynthia A; Krahn, Andrew D; Cadrin-Tourigny, Julia. - In: EUROPEAN HEART JOURNAL. - ISSN 0195-668X. - STAMPA. - 43:(2022), pp. 3041-3052. [10.1093/eurheartj/ehac289]

Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator

Targetti, Mattia;Olivotto, Iacopo;
2022

Abstract

Aims Arrhythmogenic right ventricular cardiomyopathy (ARVC) causes ventricular arrhythmias (VAs) and sudden cardiac death (SCD). In 2019, a risk prediction model that estimates the 5-year risk of incident VAs in ARVC was developed (ARVCrisk.com). This study aimed to externally validate this prediction model in a large international multicentre cohort and to compare its performance with the risk factor approach recommended for implantable cardioverter-defibrillator (ICD) use by published guidelines and expert consensus.Methods and results In a retrospective cohort of 429 individuals from 29 centres in North America and Europe, 103 (24%) experienced sustained VA during a median follow-up of 5.02 (2.05-7.90) years following diagnosis of ARVC. External validation yielded good discrimination [C-index of 0.70 (95% confidence interval-CI 0.65-0.75)] and calibration slope of 1.01 (95% CI 0.99-1.03). Compared with the three published consensus-based decision algorithms for ICD use in ARVC (Heart Rhythm Society consensus on arrhythmogenic cardiomyopathy, International Task Force consensus statement on the treatment of ARVC, and American Heart Association guidelines for VA and SCD), the risk calculator performed better with a superior net clinical benefit below risk threshold of 35%.Conclusion Using a large independent cohort of patients, this study shows that the ARVC risk model provides good prognostic information and outperforms other published decision algorithms for ICD use. These findings support the use of the model to facilitate shared decision making regarding ICD implantation in the primary prevention of SCD in ARVC.
43
3041
3052
Jordà, Paloma; Bosman, Laurens P; Gasperetti, Alessio; Mazzanti, Andrea; Gourraud, Jean Baptiste; Davies, Brianna; Frederiksen, Tanja Charlotte; Weidmann, Zoraida Moreno; Di Marco, Andrea; Roberts, Jason D; MacIntyre, Ciorsti; Seifer, Colette; Delinière, Antoine; Alqarawi, Wael; Kukavica, Deni; Minois, Damien; Trancuccio, Alessandro; Arnaud, Marine; Targetti, Mattia; Martino, Annamaria; Oliviero, Giada; Pipilas, Daniel C; Carbucicchio, Corrado; Compagnucci, Paolo; Dello Russo, Antonio; Olivotto, Iacopo; Calò, Leonardo; Lubitz, Steven A; Cutler, Michael J; Chevalier, Philippe; Arbelo, Elena; Priori, Silvia Giuliana; Healey, Jeffrey S; Calkins, Hugh; Casella, Michela; Jensen, Henrik Kjærulf; Tondo, Claudio; Tadros, Rafik; James, Cynthia A; Krahn, Andrew D; Cadrin-Tourigny, Julia
File in questo prodotto:
File Dimensione Formato  
ehac289.pdf

embargo fino al 21/11/2023

Tipologia: Pdf editoriale (Version of record)
Licenza: DRM non definito
Dimensione 1.51 MB
Formato Adobe PDF
1.51 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2158/1291307
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 5
social impact